Table 5.
Variable | Study site | Frequency (%) | P* |
---|---|---|---|
Menopausal status | 0.2917 | ||
Pre | Duke | 21 (62) | |
OSU | 15 (71) | ||
RPCI | 6 (100) | ||
Overall | 42 (69) | ||
Peri | Duke | 6 (18) | |
OSU | 5 (24) | ||
RPCI | 0 (0) | ||
Overall | 11 (18) | ||
Post | Duke | 7 (21) | |
OSU | 1 (5) | ||
RPCI | 0 (0) | ||
Overall | 8 (13) | ||
BRCA1/2 mutation | 0.1751 | ||
No | Duke | 25 (74) | |
OSU | 19 (90) | ||
RPCI | 6 (100) | ||
Overall | 50 (82) | ||
Yes | Duke | 9 (26) | |
OSU | 2 (10) | ||
RPCI | 0 (0) | ||
Overall | 11 (18) | ||
First-degree family members with breast/ovarian cancer | 0.0077 | ||
≤2 members | Duke | 31 (91) | |
OSU | 12 (57) | ||
RPCI | 5 (83) | ||
Overall | 48 (79) | ||
>2 members | Duke | 3 (9) | |
OSU | 9 (43) | ||
RPCI | 1 (17) | ||
Overall | 13 (21) |
Fisher’s exact test.